Neurocrine Biosciences Given New $17.00 Price Target at MKM Partners (NBIX)
Analysts at MKM Partners hoisted their target price on shares of Neurocrine Biosciences (NASDAQ:NBIX) from $13.00 to $17.00 in a research report issued to clients and investors on Tuesday, AnalystRatings.Net reports. The firm currently has a “buy” rating on the stock. MKM Partners’ target price suggests a potential upside of 74.18% from the stock’s previous close.
NBIX has been the subject of a number of other recent research reports. Analysts at Roth Capital raised their price target on shares of Neurocrine Biosciences from $16.00 to $22.00 in a research note to investors on Tuesday. Separately, analysts at Zacks reiterated an “outperform” rating on shares of Neurocrine Biosciences in a research note to investors on Monday. They now have a $18.00 price target on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of Neurocrine Biosciences in a research note to investors on Thursday, December 19th. They set an “overweight” rating and a $17.00 price target on the stock. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Neurocrine Biosciences currently has a consensus rating of “Buy” and an average target price of $17.78.
Neurocrine Biosciences (NASDAQ:NBIX) traded up 80.02% during mid-day trading on Tuesday, hitting $17.57. The stock had a trading volume of 8,885,010 shares. Neurocrine Biosciences has a one year low of $8.08 and a one year high of $16.74. The stock has a 50-day moving average of $9.41 and a 200-day moving average of $11.75. The company’s market cap is $1.183 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Tuesday, October 29th. The company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters consensus estimate of ($0.20) by $0.03. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share. The company’s quarterly revenue was down 92.2% on a year-over-year basis. Analysts expect that Neurocrine Biosciences will post $-0.72 EPS for the current fiscal year.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.